3/1/2004

The FDA's "approvable" letter to Sepracor for its Estorra drug allows the Massachusetts drug company to bypass additional clinical or pre-clinical trials for the drug's final approval. The company said it hopes to begin marketing the drug as early as the middle of the year.

Full Story:
NYTimes.com

Related Summaries